MESOBLAST LTD

Mesoblast, the Australian biotech leader, expands its mesenchymal‑cell platform to Duchenne muscular dystrophy, chronic pain, and heart failure, partnering with Mayo Clinic to accelerate next‑gen therapies and attract investor interest.

Mesoblast’s Ryoncil cell therapy hits $100 M+ in sales, boosting revenue and fueling expansion into new diseases, back‑pain, and heart failure treatments.

JPMorgan Chase now owns 5% of Melbourne‑based Mesoblast, the biotech firm focused on cardiovascular and cancer drugs, and its stock is trading at AUD 2.06 with a $1.73B market cap.

Discover how JPMorgan’s 5% stake in Mesoblast Limited could impact the biotech firm’s growth, drug development and investor confidence.

Mesoblast Limited, a Melbourne‑based biotech pioneer, is advancing stem‑cell therapies across cardiovascular, oncology, hematology, and orthopedics, attracting major pharma interest while navigating financial challenges and a fluctuating ASX valuati…

Explore Mesoblast Limited’s cutting‑edge regenerative therapies, its ASX stock dynamics, and future growth prospects for investors and biotech professionals.

Mesoblast Limited, a biotechnology company, has announced its financial results and operational updates, highlighting the successful FDA approval and commercial launch of its product Ryoncil, a treatment for steroid-refractory acute graft-versus-hos…